As we illustrated in network pharmacologic analysis (Fig 6), these compounds might work in combination with other active compounds to attenuate obesity via modulating major targets including PTGS2, ADRB2, and NCOA2. The gene discussed is ADRB2; the disease is obesity due to melanocortin 4 receptor deficiency.